ASCO: Bone Meds, Esophageal Cancers Linked
CHICAGO (MedPage Today) — The esophageal cancer risk with bisphosphonate bone drugs may be a bigger problem than thought, particularly with use of alendronate (Fosamax), an adverse event surveillance study suggested.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com